title: Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients.
abstract: Background: Treatment of hepatitis C virus (HCV) infection with interferon (IFN) in older patients may not be feasible on account of side effects: we, therefore, attempted combined treatment with amantadine hydrochloride (AH) in order to improve not only the flu-like symptoms associated with IFN but also the anti-viral effect. Methods: Patients over 65 years of age, (n=165), who had failed to eradicate HCV infection after previous treatment with IFN were randomized into three groups and treated for 12 months, group A received AH 100 mg twice per day; group B received IFNalpha-n(3) 6 M units every other day for 3 months followed by 3 MU and group C the same dose of IFNalpha-n(3), as in B, and AH 200 mg per day. Results: Group A, 42 patients agreed to undergo treatment (genotype 1b n=39); at the end of treatment 21 patients (50%) had normal ALT and seven (17%) negative polymerase chain reaction (PCR). HCV-RNA was not detectable in seven patients at the sixth month follow-up and in six (14%) after 23plus minus2 months. Group B, 39 patients accepted the treatment (genotype 1b n=31); at the end of treatment, 17 patients (44%) had normal ALT and 13 negative PCR (13%). HCV-RNA was not detectable in nine patients (23%) at the sixth month of follow-up and in eight (21%) after 22plus minus4 months. Group C, 38 patients accepted the treatment (genotype 1b n=32); at the end of treatment, 20 (53%) patients had normal ALT and 15 negative PCR (39%). HCV-RNA was not detectable in 15 patients at the sixth month follow-up and in 11 after 21plus minus4 months (29%). Forty-six patients did not accept the scheme of treatment and 26 of them had a follow-up of 20plus minus3 months. HCV-RNA copies and prevalence of genotype 1b were comparable to the treated groups: HCV-RNA was fluctuating or unchanged during the entire follow-up. Conclusions: AH associated with IFN was able to improve the negativization of HCV-RNA and sustained response to IFN and decreased the malaise associated with IFN; an increase in viral copies was observed under AH in about 40%.
authors.affiliation: Department of Clinical Sciences, Gastroenterology Unit, University La Sapienza, Clinica Medica 2, Policlinico, 00161, Rome, Italy
authors.forename: Marco
authors.initials: M
authors.lastname: Bacosi
authors.forename: Francesca
authors.initials: F
authors.lastname: Russo
authors.forename: Sara
authors.initials: S
authors.lastname: D'innocenzo
authors.forename: Mauro
authors.initials: M
authors.lastname: Santolamazza
authors.forename: Lucia
authors.initials: L
authors.lastname: Miglioresi
authors.forename: Antonella
authors.initials: A
authors.lastname: Ursitti
authors.forename: Anna
authors.initials: A
authors.lastname: De Angelis
authors.forename: Franca
authors.initials: F
authors.lastname: Patrizi
authors.forename: Giovanni L.
authors.initials: GL
authors.lastname: Ricci